Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: Nucl Med Biol. 2023 Dec 25;128-129:108873. doi: 10.1016/j.nucmedbio.2023.108873

Table 3:

Results from Testing of the First Production Pathway

Release Criteria Specification Test 1A Test 2A Test 3A
Appearance Clear, Colorless, No Particulates Clear, Colorless, No Particulates Clear, Colorless, No Particulates Clear, Colorless, No Particulates
Filter Integrity > 40 psi 51 psi 52 psi 52 psi
pH 4 – 8 4.5 4.5 4.5
Radiochemical Purity ≥ 90% > 99.9 % 98.4 % 99.2 %
Molar Activity ≥ 18.5 GBq/μmol
(≥ 500 Ci/mmol)
380 GBq/μmol
(10282 Ci/mmol)
415 GBq/μmol
(11238 Ci/mmol)
422 GBq/μmol
(11403 Ci/mmol)
Residual Solvent ≤ 5000 ppm MEK 0 ppm 7.58 ppm 6.84 ppm
Formulation NMT 10% EtOH 7.8 % 7.8 % 7.2 %
Total Chemical Impurities NMT 50 μg/dose 0.083 μg/mL 0.240 μg/mL 0.202 μg/mL
Activity in Final Vial 3.66 GBq
(99.0 mCi)
4.55 GBq
(122.9 mCi)
3.65 GBq
(98.7 mCi)
Concentration 295 MBq/mL
(7.97 mCi/mL)
385 MBq/mL
(10.4 mCi/mL)
296 MBq/mL
(8.0 mCi/mL)